by Nick Dragojlovic | Feb 20, 2013
– The regenerative medicine community greeted last month’s decision by the U.S. Supreme Court to uphold the legality of the Obama Administration’s stem cell policy with relief. The court found that federal funding of human embryonic stem cell (hESC) research is...
by Paul Krzyzanowski | Feb 14, 2013
– Nature kicked off 2013 with an unsettling article about how privileged information from research studies is being used to garner gigantic returns for investors, large and small. It’s not surprising, considering that one of the most egregious cases of so called...
by David Brindley | Jan 16, 2013
claimtoken-510012802486f [pullquote]The cell therapy industry has an encyclopaedic void. But is this void one that needs addressing?”[/pullquote]This post was initially intended to be a short vignette (not so short, as it turns out) exploring whether or not the...
by Paul Krzyzanowski | Jan 8, 2013
This year, your household will pay $360 for the use of Intellectual Property (IP) held by people and corporations outside of Canada. For a little less than a dollar a day, you’re supporting industries like biotechnology, high-tech electronics, and engineering in other...
by Nick Dragojlovic | Dec 20, 2012
“Stem Cells Make Aging Mice Young Again” – ABC News “’Factor X’ — Have we finally found the fountain of youth?” – Fox News “Stem cells, the secret to eternal youth?” – Euronews.com Headlines like these are all too common and underscore how the news...
by David Brindley | Nov 30, 2012
The global health care sector is innovative, impactful and, despite addressing fundamental problems in human health, can be inescapably faddish. Despite the industry’s pride in an empirical approach that yields robust and practicable data, the covers of Nature,...
Comments